SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-260380
Filing Date
2019-10-02
Accepted
2019-10-02 08:38:36
Documents
7
Effectiveness Date
2019-10-02

Document Format Files

Seq Description Document Type Size
1 DEFA14A d810618ddefa14a.htm DEFA14A 58945
2 GRAPHIC g810618gra0006.jpg GRAPHIC 8400
3 GRAPHIC g810618gra003.jpg GRAPHIC 8384
4 GRAPHIC g810618gra006.jpg GRAPHIC 8390
5 GRAPHIC g810618pca02d.jpg GRAPHIC 2789
6 GRAPHIC g810618sp005.jpg GRAPHIC 8407
7 GRAPHIC g810618spp004.jpg GRAPHIC 8361
  Complete submission text file 0001193125-19-260380.txt   95634
Mailing Address 401 TERRY AVENUE NORTH SEATTLE WA 98109
Business Address 401 TERRY AVENUE NORTH SEATTLE WA 98109 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36327 | Film No.: 191130864
SIC: 2834 Pharmaceutical Preparations